C4 Therapeutics, Inc. (CCCC) Stock Price & Analysis
C4 Therapeutics, Inc. (CCCC) closed at USD 3.18 on Thursday, October 22, 2026, up 0.32% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 3.17; the Oct 22, 2026 session ranged USD 3.12–3.25 on volume of 1,692,349 shares. Market capitalization is $391.22M, with a 52-week range of USD 1.69–5.17 (NMS). Source: Nexqual, retrieved October 23, 2026 at 12:51 UTC.
Also available as compact Markdown for AI agents: nexqual.com/CCCC.md
Key facts (CCCC)
- Last four reported quarters (through Jun 30, 2026): revenue $35.0M, net income -$101M (-289.4% margin), free cash flow -$85.4M (SEC filings).
- Analysts: Buy (mean 1.75 on a 1–5 scale) (8 analysts), mean target USD 12.86 (range 7–30).
- Total return with dividends: 1Y +33.6% vs S&P 500 +14.9%; 5Y -93.0% vs S&P 500 +80.3%.
- Next earnings: 2026-11-05, EPS estimate USD -0.21, revenue estimate $8.8M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (CCCC)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $45.8M | $31.1M | $20.8M | $35.6M | $35.9M | $35.0M |
| Operating income | -$82.1M | -$130M | -$139M | -$120M | -$115M | -$112M |
| Net income | -$83.9M | -$128M | -$132M | -$105M | -$105M | -$101M |
| EPS (diluted) | -$1.82 | -$2.62 | -$2.67 | -$1.52 | -$1.27 | — |
| Free cash flow | -$88.2M | -$111M | -$109M | -$65.3M | -$99.3M | -$85.4M |
| Operating margin | -179.4% | -416.6% | -669.8% | -336.1% | -320.5% | -319.0% |
| Net margin | -183.2% | -412.2% | -638.3% | -296.0% | -292.1% | -289.4% |
| Revenue growth | — | -32.1% | -33.3% | +71.4% | +1.0% | — |
| Cash + short-term investments | $452M | $337M | $282M | $267M | $297M | — |
| Total debt | $10.8M | $11.5M | $0K | — | — | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (CCCC)
P/S 11.2x · P/B 1.6x · FCF yield -21.83% · Earnings yield -25.92% · Buyback yield (TTM) 0.06%
Analysts (CCCC)
Consensus Buy (mean 1.75 on a 1–5 scale), 8 analysts; mean target USD 12.86 (low 7, high 30).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-09 | JP Morgan | Initiated | Overweight | $10 |
Total return (dividends reinvested) (CCCC)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +33.6% | -93.0% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +33.8% | -41.1% |
| Volatility (annualized) | 79.8% | 107.0% |
| Max drawdown | -44.1% (Jun 2026→Oct 2026) | -97.3% (Nov 2021→Apr 2025) |
CCCC suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Supplier | Pfizer (PFE) | “On September 30, 2025, we entered into a Clinical Trial Collaboration and Supply Agreement with Pfizer Inc., or the Pfizer Agreement.” |
| Partner | Merck (MRK) | “Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., or Roche, Betta Pharmaceuticals Co., Ltd., or Betta Pharma, and Merck KGaA, Darmstadt, Germany, or Merck KGaA, or other new collaboration agreements;” |
| Partner | Hoffmann-La Roche Ltd and Hoffmann-La Roche | “•We have ongoing collaborations with Roche, Betta Pharma, and Merck KGaA.” |
| Partner | Biogen MA | “This Form 10-K may also contain trademarks, service marks, and trade names of third parties, including, without limitation, our collaboration partners Roche, Biogen, Merck KGaA, and Pfizer Inc., which are the property of their respective owners.” |
| Partner | Cowen and Company | “We simultaneously entered into a sales agreement with Cowen and Company, LLC (now TD Securities (USA) LLC), as sales agent, to provide for the issuance and sale by us of up to $200.0 million of common stock from time to time in "at-the-market" offerings under the Registration Statement and related prospectus filed with the Registration Statement, or the 2021 ATM Program.” |
Quoted from the company's 10-K filed Feb 26, 2026.
CCCC company outlook (results filed Aug 11, 2026)
- “Financial Guidance: Cash, cash equivalents and marketable securities as of June 30, 2026, were $300.4 million, compared to $268.3 million as of March 31, 2026, and $297.1 million as of December 31, 2025.”
- “The company expects that its current cash, cash equivalents and marketable securities will fund its operations to the end of 2028.”
Quoted word-for-word from the SEC 8-K results press release.
CCCC analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.21 | $-0.25 | -16.0% | $8.8M | 5 |
| Next quarter (ends Dec 2026) | $-0.26 | $-0.27 | -4.3% | $4.7M | 5 |
| Current fiscal year (ends Dec 2026) | $-0.86 | $-0.96 | -10.5% | $26.4M | 5 |
| Next fiscal year (ends Dec 2027) | $-0.96 | $-1.04 | -7.5% | $22.3M | 5 |
CCCC options: expected move
Options price a move of about ±20.6% (±$0.66) by Nov 20, 2026, which includes earnings on Nov 5, 2026. Over the last 8 reports the stock moved ±10.3% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 95.8% | ±20.6% |
| Dec 18, 2026 | 56 | 110.1% | ±30.7% |
| Jan 15, 2027 | 84 | 86.8% | ±39.3% |
| Apr 16, 2027 | 175 | 96.2% | ±50.3% |
| Oct 15, 2027 | 357 | 101.6% | ±73.1% |
30-day implied volatility 103.7% vs 73.5% realized over the last 30 trading days. Put/call ratio (volume) 0. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 12:51 UTC)
| Price | USD 3.18 |
|---|---|
| Change | ▲ 0.32% (up) |
| Previous Close | USD 3.17 |
| Open | USD 3.13 |
| Day Range | USD 3.12 – 3.25 |
| 52-Week Range | USD 1.69 – 5.17 |
| Volume | 1,692,349 shares |
| Market Cap | $391.22M |
| Exchange | NMS |
Technical Analysis (CCCC)
Nexqual's technical model rates CCCC "SELL" based on 2 bullish and 4 bearish signals across 127 daily candles, as of October 23, 2026 at 12:51 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 50.79 (neutral) |
| vs SMA50 | Below (USD 3.44) |
| MACD | -0.09 (negative) |
Analyst Ratings (CCCC)
Wall Street analysts rate CCCC "Buy" based on 8 analysts, with a mean price target of USD 12.86 (range USD 7–30), per Nexqual as of October 23, 2026 at 12:51 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 12.86 |
| High Target | USD 30 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 8 / 0 / 0 |
Earnings (CCCC)
| Next Earnings Date | 2026-11-05 |
|---|---|
| EPS Estimate | USD -0.21 |
| Revenue Estimate | $8.85M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.18 vs est -0.23 ▲ beat |
| 2026-03-31 | USD -0.2 vs est -0.26 ▲ beat |
| 2025-12-31 | USD -0.18 vs est -0.39 ▲ beat |
| 2025-09-30 | USD -0.3 vs est -0.39 ▲ beat |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Financials & Fundamentals (CCCC)
| Total Revenue | $35.04M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +2.80% |
| Gross Margin | +86.34% |
| Operating Margin | -397.88% |
| Profit Margin | -289.44% |
| ROE | -48.14% |
| Debt / Equity | 0.23 |
| Current Ratio | 5.45 |
| Total Cash | $253.66M |
| Total Debt | $56.86M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$85.39M (-243.7% of revenue) |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Financial Health Score (CCCC)
Nexqual rates C4 Therapeutics, Inc.'s overall financial health "Weak" across five dimensions, as of October 23, 2026 at 12:51 UTC.
| Growth | Mixed — Revenue +1.0% YoY (annual), slow |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $254M cash vs $57M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$85M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -48%, ROA -19.3% |
Ownership (CCCC)
| Insider Ownership | +0.84% |
|---|---|
| Institutional Ownership | +104.19% |
| Shares Outstanding | 123.03M |
| Float | 94.50M |
| Short % of Float | +33.03% |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
Leadership (CCCC)
C4 Therapeutics, Inc. is led by Andrew J. Hirsch, CEO, President & Director, per Nexqual as of October 23, 2026 at 12:51 UTC.
| CEO, President & Director | Andrew J. Hirsch |
|---|---|
| Co-Founder, Independent Director & Member of Scientific Advisory Board | Kenneth C. Anderson |
| Principal Accounting Officer, CFO, Head of Corporate Affairs & Treasurer | Kendra R. Adams |
| Senior Vice President of Strategic Alliances & Business Development | Isabel Chiu |
| Senior Vice President of Chemistry | Christopher Nasveschuk |
Major Backers & Investors (CCCC)
Notable institutional backers of C4 Therapeutics, Inc. include Morgan Stanley, RA Capital Management, L.P., Lynx1 Capital Management Lp, according to Nexqual as of October 23, 2026 at 12:51 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 7.21% |
| RA Capital Management, L.P. | 6.5% |
| Lynx1 Capital Management Lp | 5.96% |
| Squadron Capital Management LLC | 5.85% |
| Bain Capital Life Sciences Investors, LLC | 5.83% |
| JPMorgan | 3.86% |
| Citadel | 3.4% |
| Wasatch Advisors LP | 3.38% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 6.42% |
| Vanguard Group | 3.59% |
Source: Nexqual, October 23, 2026 at 12:51 UTC.
From C4 Therapeutics, Inc.'s Latest SEC 10-K Filing (filed 2026-02-26)
Key Strengths & Strategy (as disclosed to the SEC)
- Leveraging our proprietary TORPEDO platform, we efficiently design and optimize small molecule protein degraders that are highly active against their desired targets by harnessing the body's natural process for destroying unwanted proteins.
- We currently are advancing two clinical programs that were developed from our proprietary TORPEDO platform and have the potential to improve patients' outcomes. ◦Develop cemsidomide as a potential best-in-class IKZF1/3 degrader: The Phase 1 trial of cemsidomide in combination with dexamethasone demonstrated a differentiated safety profile with compelling anti-myeloma activity.
- Our proprietary TORPEDO platform is an important element of our leading approach to TPD.
- Under the Roche Agreement, we agreed to collaborate with Roche in the research, development, manufacture, and commercialization of target-binding degrader medicines using our proprietary TORPEDO platform for the treatment of cancers and other indications.
Partnerships
- In May 2023, we entered into an exclusive licensing and collaboration agreement with Betta Pharma for the development and commercialization of CFT8919 in Greater China, including mainland China, Hong Kong SAR, Macau SAR and Taiwan.
- On September 30, 2025, we entered into a Clinical Trial Collaboration and Supply Agreement with Pfizer Inc., or the Pfizer Agreement.
Legal & Regulatory Risks (Item 1A, quoted)
- The FDA may impose consent decrees or withdraw approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market.
- We may seek Breakthrough Therapy designation for some or all of our current and future product candidates, including cemsidomide.
- We may also seek Orphan Drug Designations for some or all of our other current or future product candidates in additional orphan indications in which there is a medically plausible basis for the use of these product candidates.
- We may seek approval of our product candidates, where applicable, under the FDA's accelerated approval pathway. This pathway may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LGND | Ligand Pharmaceuticals Incorpor | USD 307.82 | ▼ 2.21% |
| RYTM | Rhythm Pharmaceuticals, Inc. | USD 90.9 | ▲ 2.57% |
| IOVA | Iovance Biotherapeutics, Inc. | USD 14.14 | ▼ 3.28% |
| PRAX | Praxis Precision Medicines, Inc | USD 258.92 | ▲ 0.96% |
| IONS | Ionis Pharmaceuticals, Inc. | USD 43.91 | ▼ 0.81% |
| ABVX | Abivax SA | USD 90.23 | ▼ 3.49% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 12:51 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt